FDA approves a first treatment for Alexander disease
A first-ever approval for a rare progressive neurological disorder with no previously approved treatment. An approval is not a coverage determination. Record
Closed at this snapshot: the two TGA consultations dated 3 and 4 September have passed and moved to the concluded table with their closing dates recorded.
Next 7 days
1 dated item falls in the next seven days
TGA consultation on adopting 11 international scientific guidelines closes — . Nothing else in the store falls before . The week just past is on the concluded table, not here: a passed date is a closed record, never a standing item.
Watching — open windows
11 comment windows open at the snapshot — all 11 listed here
All 11, earliest first: TGA consultation on adopting 11 international scientific guidelines — ; CMS CY 2027 Physician Fee Schedule proposed rule: comment period — ; TGA consultation closes: automated decision-making for listed-medicine applications — ; FDA docket on the Galleri multi-cancer early detection test — ; CMS draft guidance on manufacturer effectuation of the 2028 maximum fair price — ; TGA consults on releasing more medical-device safety and performance information — ; RAPID coverage pathway procedural notice (CMS-3487-NC) — ; FDA public docket on regulating generative-AI medical devices — ; FDA draft guidance on ANDA versus 505(b)(2) applications — ; FDA patient-focused drug development chronic-wounds docket closes (FDA-2026-N-5057) — ; EMA opens the revision of its overarching biosimilar guideline for comment — . Windows dated on or before have closed and moved to the concluded table with their closing dates recorded.
Representative illustration · not real people, institutions or events.
KPSGILL Weekly · The live desk · live desk · Newest permanent issue: · archive · site record current through
What changed this week, and what it changes here
This desk carries the current state of every open matter and is appended to as the week moves. The dated issues beneath it never change. As at : California’s legislative passage period has concluded. AB 2575 completed passage — Senate 21–10, Assembly concurrence 51–16 — after a refused vote and granted reconsideration four days earlier; AB 1199 completed passage 62–0; SB 903 completed passage on Senate concurrence 40–0 and is enrolling. SB 503 and SB 1023 were presented to the Governor at 6:00 PM on 30 August, SB 942 at 6:00 PM on 31 August. AB 1979 and AB 539 remain at passage complete, engrossing and enrolling. AB 1956 was signed on 28 August; AB 1760 and AB 2503 on 31 August, chapter numbers not yet recorded. None of the passed bills is law
Beyond medicine — dated records on the Everyday desk
This desk is not confined to health. The records below are insurance, utility, wage, tax and legislative documents with a date attached that reaches a household in the Central Valley, each read from the body that issued it. They are listed by how soon that date arrives.
A surveillance pass across California, the federal agencies, the European Union, the United Kingdom and the Asia-Pacific regulators. Every item below was located in the issuing body’s own publication and carries its date and instrument. Where only a secondary round-up was found, the item is marked a lead and no state is asserted.
California · AB 2575 is enrolled and unsigned. The Governor’s office has published signing lists for 22, 27 and 31 August 2026. AB 2575 appears on none of them, and no signing list has been published on or after 1 September. The measure is authored by Assemblymember Liz Ortega (D-Hayward) and would add Section 1714.48 to the Civil Code, Section 1339.76 to the Health and Safety Code, and Article 2.7 (commencing with Section 2820) to Chapter 2 of Division 3 of the Labor Code. Lifecycle: ENROLLED. Not law, not operative, no presentment established. Dossier
California · two health measures signed 31 August. AB 1760 (Arambula, D-Fresno) — Dentistry — and AB 2503 (Wallis, R-Bermuda Dunes) — California Interscholastic Federation: pupil health: heat illness: guidelines. Both are signed. A signature is not an effective date, and neither carries one on the record read. Governor’s desk
Federal · FDA approves a first treatment for Alexander disease (3 September 2026). Alexander disease is a rare progressive neurological disorder in which gene mutations trigger abnormal protein buildup in the brain’s supportive cells, damaging the nervous system. This is a first-ever approval for the condition; there were no previously approved treatment options. Lifecycle: APPROVED.
Federal · FDA opens a post-market food chemical safety programme (4 September 2026), naming reassessment of BHT and ADA. Lifecycle: PROGRAMME ANNOUNCED. A reassessment is not a restriction and establishes no duty.
Federal · a continuing resolution passed the House 370–48 on 1 September 2026, funding the government through December. It carries provisions delaying a federal redefinition of hemp products and an Office of Management and Budget policy giving political appointees more control over grantmaking. Lifecycle: PASSED ONE HOUSE. Passage by one chamber is not enactment.
Federal · comment window closes 13 October 2026 on the CMS RAPID device coverage pathway, published as a notice with comment period on 11 August 2026. RAPID does not grant automatic Medicare coverage on FDA authorisation: it synchronises the national coverage determination process so a proposed NCD can issue the same day, with a final NCD targeted within 60 to 90 days. Lifecycle: OPEN FOR COMMENT.
European Union · EMA opened a voluntary data submission pilot on 1 September 2026 for New Approach Methodologies — alternatives to animal testing. Developers may submit NAMs data and receive tailored feedback. Lifecycle: PILOT OPEN. A voluntary pilot creates no obligation and changes no requirement.
United Kingdom · MHRA published an MHRA–NICE Real-World Evidence Scientific Dialogue on 4 September 2026, alongside its register of licensed manufacturing sites and its register of brokers authorised to deal in human medicines, both dated the same day. Lifecycle: GUIDANCE AND REGISTER PUBLICATION. A scientific dialogue is neither a regulation nor a licensing requirement.
Asia-Pacific and Canada · lead only, no record entered. A 2 September 2026 industry round-up reports FDA clearances, MHRA safety and label action, Health Canada drug recalls and post-marketing safety postings from Japan’s PMDA. That is a discovery source, not an authority. Nothing from it enters a record here until located in the issuing body’s own publication.
Dated windows added to the calendar from this pass: FDA–CRGC workshop on the GLP-1 generic drug pathway, 23–24 September 2026; HHS Physician-Focused Payment Model Technical Advisory Committee, 14–15 September 2026; CMS Medicare Advisory Panel on Clinical Diagnostic Laboratory Tests, 15–16 September 2026; TANF final rule effective 29 September 2026; and FY 2027 inpatient prospective payment rates effective 1 October 2026 at a net 2.3 per cent, being a 3.2 per cent market basket increase reduced by a 0.9 point productivity adjustment.
Update — 1 September 2026 · 9:00 PM Pacific
Two California uncertainties carried through the earlier snapshots are now resolved. The two earlier blocks below — the 31 August 8:40 PM snapshot and the 1 September 1:36 PM snapshot — are preserved unchanged as historical states; each was correct for its own instant.
AB 2575 completed legislative passage on 31 August. The Senate passed it 21–10; the Assembly then took the measure without reference to file and concurred in the Senate amendments 51–16. Four days earlier the same bill had a refused passage vote. It is not law: enrollment and presentment are the next recorded states, and the 28 August amendments still need reading in full. Dossier · Record
AB 1199 completed legislative passage. Assembly concurrence 62–0 after a 13–0 committee recommendation. The bill concerns health-care provider credentialing, and it now has a canonical dossier and a Policy Lab treatment rather than a single tracker row. Dossier · Credentialing modernisation
SB 903 completed legislative passage — Senate concurrence 40–0, ordered to engrossing and enrolling. That is a later state than passed-the-Legislature and an earlier state than presented-to-Governor; the register distinguishes all three. Dossier
Presented to the Governor: SB 503 and SB 1023 at 6:00 PM on 30 August, SB 942 at 6:00 PM on 31 August. SB 942’s enrolled text carries an urgency clause providing for immediate effect if enacted — it is not operative unless and until enacted. Governor’s Desk
AB 1979 and AB 539 stay where their own records put them — passage complete, engrossing and enrolling. Neither was advanced because a neighbouring bill moved; no presentment record was located for either.
Health Canada restructures generic-drug review. Prioritisation for access, supply-disruption and first-generic submissions; deficiency responses capped at 90 days plus one extension of up to 90 more; targeted flexibility for backlogged Review-2 submissions. The agency states scientific standards and approval criteria are unchanged — the queue changed, not the bar. A separate consultation proposes prioritising some submissions involving domestic manufacturing, and expressly does not create a new approval pathway. Record · Analysis
WHO/Europe AI report — status corrected. WHO/Europe notes that the perspectives in the Knowledge Community report do not necessarily represent WHO’s formal position. It is reclassified here as a convened expert and stakeholder report: high-quality governance evidence, not WHO AI policy. Record
DOJ’s national Fraud Division names health care among its priorities. The division’s creation is an earlier event — the action date is the launch, not the date a release restated it. Organisational priority is not evidence of wrongdoing by any provider. Record
Date engine. The CY 2027 Home Health comment period closed at its stated instant, 5:00 PM EDT on 31 August, and left the open count. Russian orders 434н and 540н moved from becomes-effective to effective today. Open comment windows now stand at 11, computed from the rows the calendar renders after two duplicate dockets were merged. EMA’s PRAC meeting runs through 3 September; the TGA advertising-code consultation closes 3 September. Calendar
Live desk — 1 September 2026 · 1:36 PM Pacific
State transition, not a rewrite. The 31 August 8:40 PM edition is preserved as a historical snapshot record; what follows is what the record establishes now. Each bill moved independently after adjournment — the session ending establishes nothing about any of them.
California · AB 2575 passed the Senate 21–10. Three days after refusing passage 18–10 and granting reconsideration 40–0, the Senate read the bill a third time on 31 August and passed it on the 28 August amended text, ordering it to the Assembly. Because the Assembly passed the bill before those amendments, it must concur for passage to complete: passed the Senate and passed the Legislature are not the same state, and this desk does not yet assert the second. Two further consequences are being handled rather than glossed — the operative text is now the 28 August version, whose clinical-decision-support and clinician-override provisions have not been re-read, so analysis of the earlier version is withheld instead of carried forward. Record · Dossier
California · the Governor’s desk is now the active surface. SB 942 was enrolled and presented at 6:00 PM on 31 August and carries an urgency provision — immediate effect if enacted, which is not effect now. SB 1023 and SB 503 were presented on 30 August at 6:00 PM. SB 903 passed the Legislature on 31 August with enrollment not yet established. AB 1979 and AB 539 remain in engrossing and enrolling. AB 1760 and AB 2503 are signed, with chapter numbers and operative dates still unrecorded — not assumed to be 1 January. Governor’s desk
Global · WHO narrows the Bundibugyo vaccine question. WHO issued emergency normative guidance concluding that available evidence is insufficient to establish clinically meaningful human protection from licensed Ervebo against Bundibugyo virus, and recommends off-label use only within research protocols, with a ring randomised trial to generate the evidence. This supersedes the site’s earlier and blunter formulation: a vaccine licensed against Zaire ebolavirus is licensed for that pathogen, and that is not evidence about a different orthoebolavirus. WHO separately reports three vaccines and three therapeutics in trials in the DRC response — trial activity, not availability. Record
Global · WHO/Europe on responsible health AI. The Knowledge Community report names fragmented and biased datasets, governance gaps, unclear accountability and AI-literacy deficits as the persistent barriers, and argues that governance readiness rather than deployment speed is the measure of progress. It is not binding on anyone; its value is that an independent international body reached the conclusion this desk’s AI work rests on. Record
United Kingdom · MHRA statutory reform tabled. Three Government amendments to the Health Bill would touch medicines and device information-sharing powers, make medicines and device legislation easier to update, and support development of a future device licensing regime. Tabled is not enacted, and no licensing regime exists by virtue of tabling. The real question is whether a regulator should hold flexible power to update technical regulation without returning to Parliament — a trade-off against accountability, not a straightforward improvement. Record
United States. CMS added Hawaii to the Rural Health Transformation Program at $58 million, weighted toward ambulances, emergency communications and infrastructure — assets that restore reach rather than add clinical hours. FDA updated its PFAS-in-devices communication, distinguishing fluoropolymers used in catheters, cardiovascular implants, tubing and wound dressings from the compounds discussed in environmental contamination; that is a communication, not a recall or a rule. HHS held its child screen-use symposium and issued clinician continuing education — CE credit is not a standard of care. Hawaii · PFAS · HHS
Australia · first National Health Literacy Framework. Australia became the first of the comparator jurisdictions to state comprehension as a system property, linking low health literacy to delayed care, higher hospital use, medication error and avoidable admission. A framework, not a statute — but it makes a measurable question available: whether comprehension belongs in quality measurement rather than in patient blame. Record
Dates. California’s final passage day and the CMS CY 2027 Home Health comment window have closed and moved to the concluded table. Open comment windows now stand at 11, generated from the same array this page lists. PRAC concludes 3 September; the CY 2027 Physician Fee Schedule window closes 14 September. Calendar
Update — 31 August 2026 · 8:40 PM Pacific snapshot
Final-passage-day edition, state fixed at . California’s Senate floor session remained In Progress at the snapshot; later floor actions are intentionally excluded from this historical state and belong to the next transition. Recorded chamber action, never the calendar, determines each bill state below.
California · AB 2575 resolved. The chamber history now establishes the 28 August sequence: third reading, passage refused 18–10, reconsideration granted 40–0, amended on third reading, ordered to second reading — then read second time and returned to third reading on 30 August. On the 31 August third-reading file when the session went In Progress. Dossier
California · passage complete. AB 1979 (health care AI): Senate passage 26 August, Assembly concurrence 66–10 on 27 August — engrossing and enrolling, not law, not operative. AB 539 (prior-authorization duration): Senate passage 25 August, concurrence 64–4 on 26 August — same state; no payer obligation exists today. AB 1979 · AB 539
California · passed, Governor pending. SB 903 (AI barred from providing or advertising “therapy” if enacted), SB 1023 (injectable PrEP reimbursement through the outpatient drug benefit), SB 942 (detention health standards, passed 27 August, urgency clause if enacted). None is law; the sign-or-veto deadline is 30 September. AB 1199 sat in Assembly Unfinished Business — concurrence pending — at the last verified floor record. Tracker
California · signed 31 August. AB 1760 (Dental Practice Act) and AB 2503 (pupil exertional heat illness) in the Governor’s package. Signed is not automatically effective: chapter numbers and operative dates are recorded when the chaptered texts are.
United States. CMS: $149.3 million to Arkansas under the Rural Health Transformation Program. HHS/SAMHSA: $77 million in behavioral-health grants including $9.4 million for suicide-prevention and 988 follow-up. FDA/ICMRA: collaborative assessment completed on recombinant endotoxin testing — FDA, TGA, Health Canada, PMDA and Swissmedic with EMA lead, aligned decisions within days.
Global. WHO convened the first States Parties Committee on IHR implementation and opened the ten-year rare-disease action-plan process (a process, not a plan). The European Commission designated ChatGPT a Very Large Online Search Engine under the DSA, obligations due end-November. NHS England announced a ~100-pharmacy cardiovascular-screening pilot. TGA expanded UDI healthcare-implementation material. Mexico launched a national youth mental-health strategy. Russia’s Roszdravnadzor Order 662 (device-oversight checklists) took effect, fully pinned: order, MinJust registration 87896, publication 0001202608200005. EMA’s PRAC meets through 3 September — agenda published, outcomes pending.
Date engine. The EMA nicotine-dependence consultation closed 30 August and left the open-window count. Open comment windows now stand at 11; the CY 2027 Physician Fee Schedule window runs to 14 September. Calendar
Update — 30 August 2026
Sunday reconciliation run, state fixed at 12:00 PM Pacific. Each item was read at the issuing authority today. The Assembly stood adjourned until 2:00 PM; anything from that floor session is outside this state and is not backdated into it.
UPDATE 30 August — California. The Governor signed AB 1956 on , adding boys, with special attention in youth activities, and young men to the groups the Office of Suicide Prevention may focus on, and requiring a report to the Legislature on implementation strategies by . The statute is permissive: it creates no clinical duty, no screening mandate and no appropriation. Chapter number and operative date are not stated here — the chaptered text has not been read. Governor’s announcement · bill text
UPDATE 30 August — United States. DEA published three Decisions and Orders in the Federal Register of . A dentist’s registration (AE2384636) was revoked for want of authority to handle controlled substances in Ohio, with pending applications denied, effective . A Pompano Beach clinic’s matter, opened by immediate suspension under § 824(d) on 17 December 2025, produced a finding that lack of state pharmacy authority is an independent basis for revocation. A Virginia physician’s matter, opened by immediate suspension on 10 December 2025, was decided the same day — its ordered disposition is not stated here because only the opening allegations were read. State authority is the foundation of the federal registration, not a parallel credential. FR 2026-17592 · FR 2026-17594
UPDATE 30 August — United States. The FTC approved the final consent order in the $3.9 billion Ascension–AmSurg acquisition on (Docket C-4832), on a 2–0 vote: seven ambulatory surgery centres divested across Nashville, Panama City, Tulsa, Waco and Wichita, a compliance monitor, and ten years of prior notice for further surgery-centre acquisitions in those metros. The Commission did not block the transaction; it conditioned it. FTC
UPDATE 30 August — California · patient-facing. FDA’s MQSA safety notification for the Mammography Center of Monterey states the facility was required on to notify patients examined on or after , and their referring providers, of possible image-quality problems — and had not complied as at the posting. The facility is unaccredited, holds no active MQSA certificate, and may not lawfully perform mammography. FDA’s advice: obtain the images and reports and have them reviewed at a certified facility. FDA safety notification
UPDATE 30 August — California. SB 164, effective on enactment , added Health and Safety Code § 1728.9 barring new home health agency licences and new branch offices during a moratorium, and § 1728.95 permitting an exception on a written finding of unmet need in the proposed service area. California has now used the same instrument on hospice and on home health: freeze entry, then write the regulations the freeze buys time for. CDPH’s All Facilities Letter 26-28 implements the moratorium; its operational detail enters this record when the letter’s own text does — the codified moratorium and unmet-need exception are in force regardless. Statutory text
UPDATE 30 August — the record itself. Three standing registries now hold state that individual articles used to restate: California Legislature 2026 (one object per bill, keyed to its session), the litigation docket (a case’s own opinion is the authority, never a summary of it), and global outbreak state (state held per country, so Uganda can close while DR Congo expands). Every surface now reads one date object: record through 28 August, sources checked 30 August at noon Pacific, physician review recorded per revision.
UPDATE 30 August — AB 2575. Two irreconcilable accounts of 28 August floor activity were before this desk at the 30 August run; the chamber history read 31 August establishes the sequence — see the 31 August update above and the dossier.
Update — 29 August 2026
Friday enforcement and litigation run, additions through 8:00 PM Pacific, each read at the issuing authority. These updates fold into next Monday’s permanent issue.
UPDATE 29 August — United States. CMS states its enforcement actions have stopped more than $1.6 billion in potentially improper Medicare laboratory payments, with 157 lab providers revoked and a total spanning payment suspensions, overpayment recoupment and law-enforcement referrals (). The headline says fraudulent; the release body says potentially improper — these are administrative actions, not 157 criminal convictions. CMS newsroom
UPDATE 29 August — United States. HHS OCR opened compliance reviews of five medical schools under Title VI and §1557 (), stating expressly that it has not reached any conclusions on the merits. HHS announcement
UPDATE 29 August — United States. FDA approved Mimrylo (rusfertide) for adults with polycythemia vera not adequately controlled on existing therapy () — per FDA, the first approved PV treatment mimicking hepcidin; in VERIFY, 76.9% of treated patients needed no phlebotomy in weeks 20–32 vs 32.9% on placebo. FDA announcement
UPDATE 29 August — United States. DOJ’s Civil Rights Division announced its finding that George Washington University’s medical school intentionally discriminated by race in 2024–2025 admissions under Title VI and SFFA, with settlement negotiations next and suit if they fail (). GW disputes the conclusions. An agency finding is not a court judgment. DOJ announcement
UPDATE 29 August — United States. The Villages Health System agreed to a $541.5 million False Claims Act settlement over self-disclosed Medicare Advantage diagnosis-coding allegations, 2020–2024 (). DOJ: the resolved claims are allegations only, no liability determined; self-disclosure and cooperation were credited. DOJ announcement
UPDATE 29 August — United States. FDA approved Lisraya (brepocitinib), the first FDA-approved oral treatment for dermatomyositis in adults (): 30 mg once daily; Total Improvement Score 46.5 vs 31.2 on placebo at week 52 in a 241-patient phase 3 trial. FDA announcement
UPDATE 29 August — United States. FDA approved Rasonque (daraxonrasib), the first RAS-targeted therapy for metastatic pancreatic adenocarcinoma (): median overall survival 13.2 vs 6.7 months against chemotherapy in RASolute 302; 300 mg once daily; Project Orbis review. A standard approval on survival data — not accelerated approval. FDA approval notice
UPDATE 29 August — Global. The Bundibugyo Ebola outbreak has expanded to 60 of 151 health zones across six DRC provinces — 5,794 confirmed cases and 2,786 deaths through , per the DRC ministry’s data as relayed by ECDC (updated 28 August). WHO and Africa CDC announced the end of Uganda’s outbreak in a joint release dated 27 August; DRC launched a frontline-worker Ervebo campaign in Kisangani on 27 August. A PHEIC is not a pandemic, and Ervebo’s protection against Bundibugyo virus has not been established. ECDC
UPDATE 29 August — United States. DOJ and DEA announced a $50 million settlement with Walmart over allegations its pharmacies filled thousands of invalid controlled-substance prescriptions since 2013 (), with a DEA memorandum of agreement on future dispensing. Not an admission of liability; the resolved claims are allegations. DOJ
UPDATE 29 August — United States · California-linked. DermTech (now liquidating in Chapter 11) settled FCA allegations that it billed Medicare for melanoma tests with known quality-control failures — the U.S. receives an allowed unsecured bankruptcy claim of $5,038,011. Allegations resolved by settlement, not adjudicated; recovery depends on the estate. DOJ
UPDATE 29 August — United States · California provider. OCR’s 55th HIPAA Right of Access action: Azul Vision (31 California eye-care clinics) settles for $50,000 with a two-year corrective action plan after a January 2023 records request went unfulfilled until January 2025 (). A settlement of a potential violation, not an admission. HHS OCR
UPDATE 29 August — United States · Litigation. Twenty-three states including California sued HHS in the District of Maryland over new Title X funding conditions (), asking the court to declare them unlawful and block enforcement. A filed complaint — the characterizations are the plaintiffs’ claims; no merits ruling exists. California AG
UPDATE 29 August — United States · Litigation. The Fifth Circuit affirmed the government’s summary-judgment win over the Medicare Drug Price Negotiation Program (National Infusion Center Association v. Kennedy, No. 25-50661, , Southwick, J.): nondelegation rejected on an intelligible-principle reading, the §5000D excise tax held not a punitive fine under the Excessive Fines Clause, and no protected property or liberty interest found — Medicare participation is voluntary. Read from the slip opinion; rehearing and certiorari remain possible. Slip opinion
UPDATE 29 August — Russia. Three health-ministry instruments verified at the official publication portal: Order 696н (adult dental-care procedure, effective ), Order 434н (position nomenclature, effective ), and Order 540н (radiology rules expressly permitting registered AI-based medical devices, effective 1 September). Recorded by publication number; a reported pediatric-oncology postponement is not published — its circulating order number collides with a 2025 obstetrics instrument. pravo.gov.ru
UPDATE 29 August — California. End-of-session mechanics now govern every tracked bill: floor amendments closed ; each house must pass bills by ; the Governor acts by ; enactment by means a 1 January 2027 default effective date. Bill-by-bill states publish only from leginfo histories — tracker matrix is Monday work. Fixed dates
UPDATE 29 August — California · Legislation. From a commercial bill tracker’s action histories, pending confirmation at the chamber record: AB 1979 (health care AI) — Senate committee reported Do Pass 13 August; at that run the official history recorded no floor vote (passage completed 26–27 August; see the 31 August update). AB 2575 (health care AI) — ordered to Senate third reading 24 August after an amended Do Pass from the Appropriations suspense file; the official action history ends there, so no 28 August floor action is recorded. AB 539 (prior authorization) — cleared Senate Appropriations suspense file 3 August, then awaiting a floor vote (completed passage 25–26 August; see the 31 August update). None of the three is enrolled or law; each faces the 31 August floor-passage deadline. LegiScan · AB 2575 dossier · AB 539 dossier
UPDATE 29 August — United States. Confirmation sweep to 8:00 PM Pacific added two FDA index-level items read directly at fda.gov: the first wearable continuously monitoring both ketone and glucose levels (25 August), and a third New World screwworm veterinary EUA in three weeks (27 August, cattle). CDPH’s All Facilities Letter 26-28 implements the SB 164 home-health moratorium; its operational detail enters the record when the letter’s own text is recorded, and the statutory moratorium and unmet-need exception are already in force per the codified sections.
Update — 25 August 2026
Additions to the record through 10:00 AM Pacific, read at the issuing authority. The permanent Monday issue is the issue of 24 August; these updates fold into next Monday’s issue.
UPDATE 25 August — United States. FDA Early Alert, read at source: specific lots of CooperSurgical’s INCA Neonatal Nasal CPAP complete and replacement sets may exhibit a loose connection between the flexible tubing and the nasal cannula — loss of CPAP pressure and decreased oxygenation until restored. Do not use affected product; cease use and distribution and return; replace tubing or device if the connection loosens during use. No serious injuries or deaths reported as of the customer letter. An Early Alert is not a final recall classification. FDA Early Alert
UPDATE 25 August — United States. FDA approved Pasatru (garetosmab-grts) — per FDA, the second treatment for fibrodysplasia ossificans progressiva — to reduce new heterotopic ossification and clinician-assessed flare-ups in adults (announced ; read at fda.gov this morning). 10 mg/kg IV every four weeks, reducible to 3 mg/kg; fetal-harm warning with contraception through 6 months after the last dose. Not established safe or effective in children. FDA announcement
UPDATE 25 August — California. The Medical Board’s official outcome record remains unpublished on the record read this morning: the August meeting sits under past meetings with agendas and materials posted, and no action summary or approved minutes. Every agenda item stays PENDING — outcomes populate from the official record, never the agenda. Tracker
UPDATE 25 August — United States. FDA’s patient-focused drug development meeting on nonhealing chronic wounds is today (hybrid); written comments to docket FDA-2026-N-5057 remain open to . Fixed dates
Update — 24 August 2026
Additions to the record through 3:00 PM Pacific. Items are read at the issuing authority or carry their reporting source on the line; the permanent Monday issue is the issue of 24 August.
UPDATE 24 August — California. The Medical Board of California’s August meeting (panels 19 August; quarterly Board 20–21 August) has concluded. No action summary or approved minutes were located on the record read this morning: every agenda item’s disposition is PENDING until the Board publishes its action. Outcomes populate from the official record, never the agenda. Record · Tracker
UPDATE 24 August — California. The Medi-Cal Rx early-refill policy change for members 21 and older took effect as scheduled on and is now operational at the counter. An effective claims rule is not a benefit cut: no drug left the formulary and no member lost coverage. Record
UPDATE 24 August — United States. Three FDA device Early Alerts read at source: epidural and convenience kits that may contain recalled Huons saline (spine-proximity risks stated up to meningitis and paralysis); GE HealthCare Portrait monitoring software that can drop patients and reset alarms during updates; and Medline neonatal heated-wire breathing circuits being removed for connector thermal damage. Each reports no serious injuries or deaths as of its source date; none is a final recall classification. Record
UPDATE 24 August — California. CalRx and Amneal will supply roughly 10,000 public and charter TK–12 schools with free emergency albuterol — two inhalers and 25 spacers a year for three years — under CDPH’s statewide standing order, announced . A standing order is emergency-stock authorization, not prescribing advice. Record
UPDATE 24 August — United States. The former owner of two telemedicine companies was sentenced () to two years for a $110 million Medicare DME scheme — prepopulated orders signed without patient contact. Adjudicated by guilty plea; one defendant, not a finding about telemedicine. Record
UPDATE 24 August — United States. A nine-count S.D.N.Y. indictment unsealed charges four members of the Bronx “War Room” with racketeering, fraud, narcotics and firearms offenses: at least $12 million in alleged Medicaid transportation claims built on GPS-spoofed rides never provided, with kickbacks to patients in cash and drugs. An indictment is an allegation; all defendants are presumed innocent. DOJ
UPDATE 24 August — United Kingdom. The MHRA issued Class 2 Medicines Recall EL(26)A/37 (): one batch of Fingolimod Zentiva 0.5 mg capsules, precautionary, for potential metal-particle contamination found in shelf-life testing — low stated risk, no reports of harm. Patients should not stop fingolimod without speaking to a clinician. gov.uk
UPDATE 24 August — Global. WHO and Africa CDC announced () the ICG’s initial release of 70,000 Ervebo doses to the DRC: 50,000 for frontline and health workers per SAGE recommendations, 20,000 for a Phase 3 trial against Bundibugyo virus — against which Ervebo’s protection in humans is not established. An allocation is a supply decision, not an efficacy finding. WHO
UPDATE 24 August — United States. FDA granted accelerated approval to Genglycos (), the first therapy for glycogen storage disease type Ia — approved on a cornstarch-reduction surrogate endpoint, with confirmatory trials still required. Record
UPDATE 24 August — United States. The United States and Illinois filed a joint FCA complaint in intervention (announced ) alleging more than $5.2 million in podiatry claims billed under other physicians’ names after Dr. Vadim Goshko’s 2019 Medicaid termination. Allegations only; no liability determined. DOJ
Open matters — current state
Each of these remains in force or open as at 19 August 2026. Records first published in a dated issue keep that issue as their permanent home; this page carries their current state.
IN FORCE01 · California
California AI Transparency Act is now operative
· Bus. & Prof. Code ch. 25 (SB 942, as amended by AB 853)
Chapter 25 became operative August 2, 2026. AB 853 moved the original January 1, 2026 date and added later phases. Covered providers — producers of a publicly accessible generative AI system with more than one million monthly visitors or users in California — must make a free AI detection tool available, offer a manifest disclosure option, and embed latent disclosures in AI-generated image, video and audio content. Text is not covered by the disclosure duties. Large online platform and GenAI hosting duties begin January 1, 2027; capture device manufacturer duties January 1, 2028.
Why it matters here. Health systems and clinical vendors that generate synthetic patient-facing media, and any practice deploying a consumer-facing generative tool, need to know whether they are a covered provider or merely a deployer. This is a content-provenance statute, not a clinical-safety statute, and must not be cited as if it regulates diagnostic AI.
EU AI Act Article 50 transparency obligations now apply
· Regulation (EU) 2024/1689, Art. 50
Article 50 applies from 2 August 2026. It requires providers and deployers to disclose direct interaction with an AI system, mark AI-generated or manipulated content in machine-readable form, notify individuals exposed to emotion recognition or biometric categorisation, and label deep fakes and AI-generated text published on matters of public interest. The Commission adopted final implementation guidelines on 20 July 2026; those guidelines are non-binding, and only the Court of Justice can give an authoritative interpretation. Content generated before 2 August 2026 does not have to be labelled retroactively.
Why it matters here. This is the closest international analogue to the California act, and the two took effect on the same day by design. Any comparison must keep the difference visible: Article 50 also covers interaction disclosure and emotion recognition, and it reaches non-EU providers whose output is used in the EU.
CMS placed the rule on public display July 14, 2026 and published it in the Federal Register July 16, 2026. The comment period closes at close of business September 14, 2026, and finalized policies would generally take effect January 1, 2027. The one-year 2.50% conversion-factor increase provided for CY 2026 does not carry into CY 2027. CMS proposes that where a separately identifiable office or outpatient E/M visit is furnished on the same day as a 0-, 10- or 90-day global procedure, the most expensive service is paid at 100% and other same-day surgical procedures or E/M visits at 50%. The rule proposes work and practice-expense RVU changes across more than fifty code families and carries requests for information on redesigning primary care payment and on alternatives to the CPT and RUC valuation process.
Why it matters here. This is a dossier, not a single article: payment, MIPS and value-based care, primary care redesign, telehealth and remote monitoring each move separately. The comment deadline is the only date on this page a practice can still act on directly.
CMS-0062-P would extend electronic prior authorization to drugs
· CMS-0062-P, Interoperability Standards and Prior Authorization for Drugs
The rule was published in the Federal Register on April 14, 2026 and the comment period closed June 15, 2026. It is proposed, not final. CMS-0057-F built the prior-authorization API infrastructure for non-drug items and services and deliberately excluded drugs; CMS-0062-P would extend electronic prior authorization, shortened decision timeframes and public reporting to drugs under both the medical and pharmacy benefit, require impacted payers to report interoperability API endpoints and usage metrics to CMS, and adopt certain HL7 FHIR standards under HIPAA Administrative Simplification. Most proposed provisions carry an October 1, 2027 compliance date.
Why it matters here. A correction to a widely repeated summary: this rule did not issue in July 2026, and its comment period is not open. Any KPSGILL page describing it must say proposed, must not present the October 2027 dates as current duties, and must be revised when a final rule issues.
ADMINISTRATIVE CHANGE05 · United States — HRSA / NPDB
NPDB merges One-Time Query and Continuous Query into NPDB Query
· National Practitioner Data Bank service change
On December 4, 2026 the NPDB will release NPDB Query, merging Individual One-Time Query and Continuous Query. Existing Continuous Query enrollments transfer automatically and require no action. Organizations still relying on One-Time Query need a transition plan; since March 13, 2026 they have been able to export a file of One-Time Query subjects and import it into Continuous Query as new enrollments, with a validation report identifying invalid, incomplete or duplicate subjects. Since July 2026 enrollment duration is selectable from one day to twelve months, a cancelled enrollment can be resumed within the enrollment period, and an enrollment can be ended immediately after the initial response completes.
Why it matters here. Credentialing offices that still run One-Time queries at recredentialing intervals are the ones affected. The change is operational rather than legal — what the NPDB reports, and a practitioner’s dispute rights, are unchanged — and should not be described as a change to reportable events.
DHCS issued an updated regulatory provider bulletin, effective July 23, 2026, restating that clinicians who order, refer or prescribe for Medi-Cal members must be enrolled in Medi-Cal under their individual Type 1 NPI. Medicare enrollment alone, and managed-care plan affiliation alone, do not satisfy the requirement; claims associated with an unenrolled ORP NPI can be denied. Medi-Cal Rx had set June 26, 2026 as the date it would begin denying pharmacy claims and prior authorizations for unenrolled prescribers. As of mid-August 2026 the California Medical Association reports that DHCS has moved toward phased implementation and has not announced a new enforcement date.
Why it matters here. The underlying obligation is long-standing federal and state law; what is genuinely unsettled is the enforcement calendar. A physician-facing article must not state a single hard deadline. The practical action — verify individual Type 1 NPI enrollment status in PAVE now — is unaffected by the date question.
Each item above attaches to pages already in the Policy library rather than generating a duplicate essay. These pages need review against the developments recorded here.
Every date below is fixed by an instrument or by the authority’s own published listing, and every row is generated from the dated record store rather than typed here. Each carries its jurisdiction, its issuing body, and exactly one state — the state comes from the instrument, never from the position of the row. 11 comment windows are open. A date that passes keeps its row and carries its transition; it is not removed.
Swipe the table sideways for the remaining columns
Fixed dates as at — 52 entries, earliest first, running to 2031
A fixed date is not a duty. A comment deadline closes an opportunity to be heard; an effective date starts an obligation; an event date means a body is meeting, not that it has decided.
Live desk — 1 September 2026 · 1:36 PM Pacific
Post-session reconciliation edition. The 31 August 8:40 PM snapshot below is preserved unchanged — it was correct for that instant. California’s final passage period has now concluded and the state has moved to the gubernatorial phase.
AB 2575 passed the Senate 21–10 on 31 August on its amended text and was ordered to the Assembly. It is not passed the Legislature: the Senate amended the bill after Assembly passage, so the Assembly must concur, and that roll call is not established on the record read at this snapshot. Dossier · Record
Three bills are now enrolled and presented to the Governor. SB 942 (civil detainees: bill of rights) at 6:00 PM on 31 August — the enrolled bill carries an urgency provision for immediate effect if enacted, which is not the same as being in force. SB 503 (health care AI) and SB 1023 (injectable PrEP reimbursement) at 6:00 PM on 30 August. Governor’s Desk
SB 903 remains at passed-the-Legislature. Enrolment and presentment were sought and are not established at this snapshot; the register says so rather than promoting the state. AB 1199’s final concurrence roll call is likewise unresolved and is recorded as unresolved. SB 903 · AB 1199
WHO: Ervebo protection against Bundibugyo virus is unestablished. New emergency normative guidance concludes the evidence is insufficient to establish clinically meaningful human protection against BDBV and recommends off-label use only within research protocols, alongside a ring randomised controlled trial and continued proven outbreak-control measures. Three vaccines and three therapeutics are reported in trials in the DRC response — trial activity, not availability. Guidance record
WHO/Europe publishes the Responsible AI in Health report. Fragmented and biased datasets, governance gaps, unclear accountability and AI-literacy deficits; its central claim is that governance readiness, not deployment speed, is the measure of progress. It now anchors the KPSGILL AI Governance Readiness Framework and the comparative mapping of California’s health-AI bills against WHO’s principles.
United Kingdom: three Health Bill amendments tabled affecting the MHRA statutory framework — information sharing, easier updating of medicines and device legislation, and authority supporting a future device licensing regime. Tabled, not enacted. Tracker
CMS adds Hawaii to the Rural Health Transformation Program at $58 million, joining Arkansas at $149.3 million. The new spending matrix compares what each state is buying: Hawaii bought transport and communications, Arkansas bought clinical reach. No award states an outcome metric.
Also recorded. HHS held its Live Real Life symposium on children’s screen use with clinician CE attached — educational material, not a clinical guideline. FDA updated its PFAS-in-devices material, distinguishing fluoropolymers used in catheters and implants from environmental PFAS — no recall and no rule; see the new analysis on chemical-class regulation and device-specific risk. Australia launched its first National Health Literacy Framework, now analysed as system infrastructure. NHS England began phase one of its flu campaign. TGA added eight entries to its unaffected respiratory-device list — an unaffected list, not a recall.
Date engine. The EMA nicotine consultation closed 30 August and the CMS home-health comment window closed on 31 August; both moved to concluded. 11 comment windows are open, and that figure is generated from the same rows the calendar renders. Calendar
Three policies we would change this week
The weekly closing question, answered from this week's record. Each is a standing KPSGILL proposal — a policy position, not a statement of law.
